Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Betaine Addition to Water Loading Prior to Running Exercise

18 september 2026 bijgewerkt door: Emilia Zawieja, Poznan University of Life Sciences

Effects of a Betaine-Supplemented Hydration Protocol on Sweat Rate and Exercise Performance in Runners

This randomized, double-blind, placebo-controlled crossover study will investigate whether acute betaine ingestion as part of a pre-exercise hyperhydration strategy improves endurance running performance and influences hydration-related responses during prolonged exercise.

Approximately 30 recreationally trained male and premenopausal female runners will complete two experimental trials: a betaine condition and a placebo/control condition. In the betaine condition, participants will ingest anhydrous betaine at a dose of 0.07 g/kg body mass as part of a standardized pre-exercise hydration protocol providing a total fluid intake of approximately 25 mL/kg body mass.

Following the hydration protocol, participants will complete 60 minutes of treadmill running at 60% of the running velocity corresponding to VO₂max, followed by a 5-minute recovery period and a 5-km treadmill time trial.

The primary outcome will be 5-km running time-trial performance. Secondary outcomes will include exercise-induced fluid and sweat loss, urinary hydration markers, sweat electrolyte concentrations, physiological responses, exercise economy, substrate utilization, blood lactate concentration, perceived exertion, thirst, and thermal sensation.

Studie Overzicht

Toestand

Nog niet aan het werven

Conditie

Studietype

Ingrijpend

Inschrijving (Geschat)

20

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 45 jaar (Volwassen)

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Age 18-45 years
  • Sex: men and premenopausal women
  • Continuous running training for at least 12 months
  • At least 3 running training sessions per week
  • Willingness and ability to complete the treadmill exercise protocol: 60 minutes of running at 60% of the running velocity corresponding to VO₂max, followed by a 5-km running time trial
  • Medical clearance for participation in maximal and prolonged exercise testing

Exclusion Criteria:

  • Age <18 or >45 years
  • Postmenopausal women
  • Use of betaine, choline, folic acid/folate, or vitamin B12 supplements within 3 months prior to study participation
  • Current musculoskeletal injury or injury occurring within the previous 2 months
  • Uncontrolled arterial hypertension
  • Pregnancy or breastfeeding
  • Diabetes requiring insulin therapy or inadequately controlled diabetes
  • Active or severe liver disease, including ALT or AST >3× the upper limit of normal
  • Renal impairment, including eGFR <60 mL/min/1.73 m²
  • Untreated or unstable thyroid disease, including hypothyroidism or hyperthyroidism
  • Gastrointestinal disease that may affect nutrient absorption
  • Kidney disease, cardiovascular disease, irritable bowel syndrome, or adrenal disease
  • Use of diuretics, SGLT2 inhibitors, laxatives, or glucocorticoids
  • Any medical contraindication to physical exercise and/or failure to obtain medical clearance for exercise testing
  • Elevated body temperature at the time of testing
  • Cystic fibrosis

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Ander
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Crossover-opdracht
  • Masker: Verdrievoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Betaine → Placebo Sequence

Participants will first complete the betaine-enriched hyperhydration condition. After the washout period, they will complete the placebo hyperhydration condition.

Anhydrous betaine (trimethylglycine) will be administered as a single dose of 0.07 g/kg body mass, dissolved in a commercially available sports drink (5 mL/kg body mass), 150 minutes before exercise. The betaine-containing drink will constitute the first bolus of a standardized pre-exercise hyperhydration protocol providing a total fluid intake of approximately 25 mL/kg body mass over 120 minutes.

Participants will receive the same commercially available sports drink (5 mL/kg body mass) without added betaine 150 minutes before exercise. This will be followed by four additional fluid boluses of mineral water (5 mL/kg each) administered at 120, 90, 60, and 30 minutes before exercise, for a total pre-exercise fluid intake of approximately 25 mL/kg body mass.

Experimenteel: Placebo → Betaine Sequence

Participants will first complete the placebo hyperhydration condition. After the washout period, they will complete the betaine-enriched hyperhydration condition.

Anhydrous betaine (trimethylglycine) will be administered as a single dose of 0.07 g/kg body mass, dissolved in a commercially available sports drink (5 mL/kg body mass), 150 minutes before exercise. The betaine-containing drink will constitute the first bolus of a standardized pre-exercise hyperhydration protocol providing a total fluid intake of approximately 25 mL/kg body mass over 120 minutes.

Participants will receive the same commercially available sports drink (5 mL/kg body mass) without added betaine 150 minutes before exercise. This will be followed by four additional fluid boluses of mineral water (5 mL/kg each) administered at 120, 90, 60, and 30 minutes before exercise, for a total pre-exercise fluid intake of approximately 25 mL/kg body mass.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
5-km Running Time-Trial Performance
Tijdsspanne: During the 5-km treadmill time trial performed after the 60-minute running preload and a 5-minute recovery period in each experimental trial.

Time required to complete a 5-km treadmill running time trial, expressed in seconds. Participants will be instructed to complete the distance as quickly as possible and will be allowed to adjust treadmill speed throughout the trial. Lower completion time indicates better performance.

During the 5-km treadmill time trial performed after the 60-minute running preload and a 5-minute recovery period in each experimental trial.

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Sweat rate
Tijdsspanne: From immediately before the 60-minute running preload to completion of the subsequent 5-km time trial during each experimental trial.

Whole-body sweat rate will be estimated from the change in body mass from immediately before exercise to completion of the 5-km time trial, adjusted for fluid intake and urine output, if applicable, and expressed as L/h. Body mass will be measured using the calibrated electronic scale integrated with the BOD POD system (COSMED, Italy) and expressed in kilograms (kg). Changes in body mass will also be calculated and reported as a percentage of pre-exercise body mass (%).

From immediately before the 60-minute running preload to completion of the subsequent 5-km time trial during each experimental trial.

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Sweat sodium concentration
Tijdsspanne: Between minutes 30 and 60 of the 60-minute running preload during each experimental trial.

Sodium concentration will be measured in sweat samples collected from standardized sites on the forearm and thigh during exercise. Sweat samples will be collected between minutes 30 and 60 of the 60-minute running preload. Sodium concentration will be analyzed using a HORIBA ion-selective electrode analyzer and reported in mmol/L.

Between minutes 30 and 60 of the 60-minute running preload during each experimental trial.
Sweat Potassium Concentration
Tijdsspanne: Between minutes 30 and 60 of the 60-minute running preload during each experimental trial.

Potassium concentration will be measured in sweat samples collected from standardized sites on the forearm and thigh during exercise. Sweat samples will be collected between minutes 30 and 60 of the 60-minute running preload. Sweat potassium concentration will be analyzed using a HORIBA ion-selective electrode analyzer and reported in mmol/L.

Between minutes 30 and 60 of the 60-minute running preload during each experimental trial.
Blood lactate concentration
Tijdsspanne: Immediately after the 60-minute running preload and immediately after the 5-km time trial during each experimental trial.

Blood lactate concentration will be measured using a portable Lactate Scout 4 analyzer. Measurements will be obtained immediately after completion of the 60-minute running preload and immediately after completion of the subsequent 5-km time trial. Blood lactate concentration will be reported in mmol/L.

Immediately after the 60-minute running preload and immediately after the 5-km time trial during each experimental trial.
Heart rate
Tijdsspanne: Continuously during the 60-minute running preload and the subsequent 5-km time trial in each experimental trial.

Heart rate will be monitored continuously using a Garmin chest-strap heart rate monitor with integrated electrodes throughout the 60-minute running preload and the subsequent 5-km time trial. Outcome variables will include mean heart rate during the 60-minute preload, mean heart rate during the 5-km time trial, and maximal heart rate achieved during the 5-km time trial. Heart rate will be reported in beats per minute (bpm).

Continuously during the 60-minute running preload and the subsequent 5-km time trial in each experimental trial.
Core Body Temperature
Tijdsspanne: Continuously during the 60-minute running preload and the subsequent 5-km time trial in each experimental trial.

Core body temperature will be monitored continuously using a CORE body temperature sensor attached to the Garmin chest strap throughout the 60-minute running preload and the subsequent 5-km time trial. Outcome variables will include mean core body temperature during the exercise protocol and the highest core body temperature recorded during the exercise protocol. Temperature will be reported in degrees Celsius (°C).

Continuously during the 60-minute running preload and the subsequent 5-km time trial in each experimental trial.
Running Economy
Tijdsspanne: During the final 10 minutes (minutes 50-60) of the 60-minute running preload in each experimental trial.

Running economy will be assessed by breath-by-breath indirect calorimetry using a QUARK RMR metabolic system during the final 10 minutes (minutes 50-60) of the 60-minute running preload. Running economy will be quantified as mean oxygen consumption (VO₂) relative to body mass at the standardized running velocity and expressed as mL·kg-¹·min-¹. Lower oxygen consumption at the same running velocity indicates better running economy.

During the final 10 minutes (minutes 50-60) of the 60-minute running preload in each experimental trial.
Respiratory Exchange Ratio
Tijdsspanne: During the final 10 minutes (minutes 50-60) of the 60-minute running preload in each experimental trial.

Respiratory exchange ratio (RER) will be assessed by breath-by-breath indirect calorimetry using a QUARK RMR metabolic system during the final 10 minutes (minutes 50-60) of the 60-minute running preload. RER will be calculated as the ratio of carbon dioxide production (VCO₂) to oxygen consumption (VO₂) and expressed as a unitless value. The mean RER over the measurement period will be used for analysis.

During the final 10 minutes (minutes 50-60) of the 60-minute running preload in each experimental trial.
Urine specific gravity
Tijdsspanne: Immediately before the 60-minute running preload and immediately after completion of the 5-km time trial in each experimental trial.

Urine specific gravity (USG) will be measured using a URIT-31 urine analyzer from urine samples collected immediately before the 60-minute running preload and after completion of the subsequent 5-km time trial. USG will be reported as a dimensionless value. Urine osmolality will also be estimated from USG using a predefined conversion equation and reported in mOsm/kg.

Immediately before the 60-minute running preload and immediately after completion of the 5-km time trial in each experimental trial.
Rating of Perceived Exertion (RPE)
Tijdsspanne: At minutes 30, and 60 of the 60-minute running preload and immediately after completion of the 5-km time trial during each experimental trial.

Rating of perceived exertion will be assessed using the Borg 6-20 Rating of Perceived Exertion scale, ranging from 6 ("no exertion at all") to 20 ("maximal exertion"). RPE will be recorded at 15-minute intervals during the 60-minute running preload and immediately after completion of the 5-km time trial.

At minutes 30, and 60 of the 60-minute running preload and immediately after completion of the 5-km time trial during each experimental trial.
Thirst Sensation
Tijdsspanne: Immediately before the 60-minute running preload, at minutes 30,and 60 of the preload, and immediately after completion of the 5-km time trial during each experimental trial.

Perceived thirst will be assessed using a 9-point categorical thirst sensation scale ranging from 1 ("not thirsty at all") to 9 ("very, very thirsty"). Participants will be asked to rate their current sensation of thirst at each measurement time point.

Immediately before the 60-minute running preload, at minutes 30,and 60 of the preload, and immediately after completion of the 5-km time trial during each experimental trial.
Thermal Sensation
Tijdsspanne: Immediately before the 60-minute running preload, at minutes 30 and 60 of the preload, and immediately after completion of the 5-km time trial during each experimental trial.

Thermal sensation will be assessed using a 17-point thermal sensation scale ranging from 0 to 8 in 0.5-point increments, with 0 representing "unbearably cold", 4 representing "neutral", and 8 representing "unbearably hot". Participants will rate their whole-body thermal sensation at each measurement time point.

Immediately before the 60-minute running preload, at minutes 30 and 60 of the preload, and immediately after completion of the 5-km time trial during each experimental trial.

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 oktober 2026

Primaire voltooiing (Geschat)

31 mei 2027

Studie voltooiing (Geschat)

30 december 2027

Studieregistratiedata

Eerst ingediend

18 september 2026

Eerst ingediend dat voldeed aan de QC-criteria

18 september 2026

Eerst geplaatst (Werkelijk)

25 september 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

25 september 2026

Laatste update ingediend die voldeed aan QC-criteria

18 september 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • BETxSWEAT

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

ONBESLIST

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren